Guidelines for the pharmacological treatment of anxiety disorders, obsessive-compulsive disorder and posttraumatic stress disorder in primary care.
about
Pregabalin for the treatment of generalized anxiety disorder: an updateBridging the gap between education and appropriate use of benzodiazepines in psychiatric clinical practiceAnxiety disorders and GABA neurotransmission: a disturbance of modulationPharmacology of cognitive enhancers for exposure-based therapy of fear, anxiety and trauma-related disordersCombined Neuropeptide S and D-Cycloserine Augmentation Prevents the Return of Fear in Extinction-Impaired Rodents: Advantage of Dual versus Single Drug Approaches.Mexazolam: clinical efficacy and tolerability in the treatment of anxietyStimulation of 5-HT2C receptors improves cognitive deficits induced by human tryptophan hydroxylase 2 loss of function mutationBenzodiazepine Use, Misuse, and Harm at the Population Level in Canada: A Comprehensive Narrative Review of Data and Developments Since 1995.The relevance of 'mixed anxiety and depression' as a diagnostic category in clinical practicePatient satisfaction with specialized mental health service for obsessive-compulsive disorder.Goal-directed learning and obsessive-compulsive disorder.Pregabalin: a review of its use in adults with generalized anxiety disorder.Stereotypical behaviors in chimpanzees rescued from the african bushmeat and pet trade.Clinical characteristics of the respiratory subtype in panic disorder patientsPharmacological treatment for generalized anxiety disorder in adults: an update.Vilazodone in patients with generalized anxiety disorder: a double-blind, randomized, placebo-controlled, flexible-dose study.Efficacy and safety of duloxetine in the treatment of older adult patients with generalized anxiety disorder: a randomized, double-blind, placebo-controlled trialModeling the longitudinal latent effect of pregabalin on self-reported changes in sleep disturbances in outpatients with generalized anxiety disorder managed in routine clinical practice.The efficacy and safety of multiple doses of vortioxetine for generalized anxiety disorder: a meta-analysis.Differential interactions engendered by benzodiazepine and neuroactive steroid combinations on schedule-controlled responding in rats.Antipsychotic Augmentation of Serotonin Reuptake Inhibitors in Treatment-Resistant Obsessive-Compulsive Disorder: An Update Meta-Analysis of Double-Blind, Randomized, Placebo-Controlled Trials.Epigenetic Modulation of Mood Disorders.The efficacy of psychotherapy and pharmacotherapy in treating depressive and anxiety disorders: a meta-analysis of direct comparisons.Treatment of anxiety in patients with coronary heart disease: Rationale and design of the UNderstanding the benefits of exercise and escitalopram in anxious patients WIth coroNary heart Disease (UNWIND) randomized clinical trialGenetic markers of a Munc13 protein family member, BAIAP3, are gender specifically associated with anxiety and benzodiazepine abuse in mice and humans.Standards of care for obsessive-compulsive disorder centresPost Hoc Analyses of Anxiety Measures in Adult Patients With Generalized Anxiety Disorder Treated With Vilazodone.Comparison of group cognitive behavioral therapy and interactive lectures in reducing anxiety during pregnancy: A quasi experimental trial.Adding psychotherapy to antidepressant medication in depression and anxiety disorders: a meta-analysis.Clinical Practice Guidelines for the Management of Generalised Anxiety Disorder (GAD) and Panic Disorder (PD).New approaches to the pharmacological management of generalized anxiety disorder.Evaluation of the pharmacokinetics, safety and clinical efficacy of sertraline used to treat social anxiety.Pharmacotherapy of generalized anxiety disorder: focus and update on pregabalin.Role of atypical antipsychotics in the treatment of generalized anxiety disorder.The German guidelines for the treatment of anxiety disorders.Pharmacokinetic evaluation of fluvoxamine for the treatment of anxiety disorders.Utilization of psychotropic drugs prescribed to persons with and without HIV infection: a Danish nationwide population-based cohort study.Phytopharmaceutical treatment of anxiety, depression, and dementia in the elderly: evidence from randomized, controlled clinical trials.Efficacy and safety of pregabalin in generalised anxiety disorder: A critical review of the literature.Anxiety in Patients with Schizophrenia: Epidemiology and Management.
P2860
Q24604809-716435FC-07B5-4837-B5A2-48C2FCE3E845Q26800235-4772A1DE-995D-486A-94D8-CB3881BBBF8BQ27003916-675FFFA0-5846-485E-9E25-5B43C164570DQ27006437-91F95F52-2D8D-4A76-8F93-647711132DAEQ27300710-A432CB3B-A488-4CAC-B56C-56EB1143BFEFQ28084954-0C2C7DD6-984C-4240-8F64-CBA5C9068FC9Q28301428-E9BD5313-644A-492D-B2FE-ADBEEA628413Q30251634-ED0E749B-4058-4304-BFE8-99F36BFA1848Q30251737-8A241EE9-6B00-48F4-9E81-D4AF8525DE09Q33643395-3522BE86-764C-4C56-8CFD-D7BE480EF10EQ34291912-83FC97E9-2326-4FB8-96EB-8F7054EFDBBEQ34434641-41DB4DF2-D96B-4F4C-B1D8-C65295FB3FFBQ34443188-83141C8C-30D2-4A71-A16E-26CCA5BB8146Q34476468-B9A83A73-8D07-4C8D-B4F8-9B4D887CF041Q34484276-9DCFB8C8-3D94-42EA-B9A2-A8E49995808AQ34672417-7A915FE3-5ED6-4A24-BC13-8736D1006A5CQ34853281-C55E1477-0923-4705-86CD-79C6AB432BB9Q35939600-7A67D157-50CF-4D7D-9639-C5B4F2EDFA88Q36008269-500E2DF5-9015-4F4B-8AA9-030CE060BF4AQ36054271-FAE92C78-35EC-4A7E-8F9A-1C8C5EED8CBAQ36077216-939DB7E6-816E-438C-90CB-3A5AEF39162CQ36737217-35D73FE1-F4FA-45C6-8436-D4A630B49EB9Q36930878-745088A5-61C9-49E8-B731-9EBB27C777BCQ36987340-D6792926-E496-46F6-8558-ECE337783D5EQ37100288-97A90B6A-58E8-4AAA-9739-6C34752C3E10Q37107260-BBB144C8-CDE2-47C9-AD7E-2F690E0045D3Q37115879-FFDC9262-0E7E-4166-AE18-061234F90CA8Q37384185-2689B50F-21E0-4F1C-AC1F-F9E90AFC7A7CQ37568585-9AA603AF-611F-4E89-9306-A3E01DA6A764Q37643041-A5D1B50D-47AE-4ED1-899E-C4D4BFA8CC83Q38071131-4B38FF15-8DAF-4FB0-AD78-E99EA168B75AQ38120061-D699F7BC-D413-49F7-A2F6-87E2E7C7569AQ38168858-169CB70B-59FE-48F2-A6A6-1591239D330BQ38209188-6A7A0796-5648-4873-AC4F-276636152B3BQ38268948-F009FB0C-CECF-4BBF-A899-57920B73C827Q38366480-EA1DA8C3-49F3-4EFC-A615-AFE404C54670Q38421984-3BE65C04-C19C-4255-80D0-B3C7D219286AQ38532642-29ABAF3A-C142-4334-A9F5-9EE9E2905708Q38563874-7FBFA36D-A84B-4F9B-BA2E-41513ED2FD4EQ38611406-3E2FA761-DEF6-4040-A4D4-2DAB40B0678C
P2860
Guidelines for the pharmacological treatment of anxiety disorders, obsessive-compulsive disorder and posttraumatic stress disorder in primary care.
description
2012 nî lūn-bûn
@nan
2012 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Guidelines for the pharmacolog ...... ress disorder in primary care.
@ast
Guidelines for the pharmacolog ...... ress disorder in primary care.
@en
Guidelines for the pharmacolog ...... ress disorder in primary care.
@nl
type
label
Guidelines for the pharmacolog ...... ress disorder in primary care.
@ast
Guidelines for the pharmacolog ...... ress disorder in primary care.
@en
Guidelines for the pharmacolog ...... ress disorder in primary care.
@nl
prefLabel
Guidelines for the pharmacolog ...... ress disorder in primary care.
@ast
Guidelines for the pharmacolog ...... ress disorder in primary care.
@en
Guidelines for the pharmacolog ...... ress disorder in primary care.
@nl
P2093
P50
P1476
Guidelines for the pharmacolog ...... ress disorder in primary care.
@en
P2093
Eric Hollander
Joseph Zohar
Robertas Bunevicius
WFSBP Task Force on Anxiety Disorders, OCD and PTSD
WFSBP Task Force on Mental Disorders in Primary Care
P356
10.3109/13651501.2012.667114
P577
2012-04-30T00:00:00Z